Research digest
Ipamorelin was built to do one thing cleanly: trigger a growth hormone pulse without dragging cortisol and prolactin along with it.
A forward-looking digest of the published literature — the selectivity data, the human pharmacokinetics, the one trial that failed, and what people report — with every figure carried back to the study that measured it.
The short version
Ipamorelin is a tiny lab-made peptide — a chain of just five amino acids. Its one job is to tap a single receptor in the brain's master gland (the pituitary) and make it release a quick pulse of growth hormone, the body's signal for repair and rebuilding. What made ipamorelin a landmark when it was first described is that it does this cleanly. Older peptides that release growth hormone also spiked stress hormones like cortisol and prolactin; ipamorelin mostly does not [1]. That clean, on-target pulse is the whole story here.
What do people use it for? In research-use circles, the most common reasons are better sleep, faster recovery, and a slow shift toward leaner body composition. The honest state of the evidence: animal data is strong on the selectivity itself, but human data is thin — and the one real human trial, for a gut-recovery condition, did not work [3]. Ipamorelin is not an approved medicine anywhere, and nothing here is sold, prescribed, or dosed. The downsides people report — a warm facial flush, more hunger, mild puffiness — and who should be careful are laid out on Ipamorelin effects.
One receptor, one clean pulse
Ipamorelin (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a selective agonist of the ghrelin receptor, formally the growth hormone secretagogue receptor type 1a, or GHS-R1a (the docking site that the body's own "hunger hormone" ghrelin normally uses). When ipamorelin binds it, pituitary somatotrophs — the cells that make growth hormone — fire off a discrete GH pulse [1].
The defining result, from the 1998 founding paper, is what didn't move. In rats and conscious swine, ipamorelin released GH about as potently as the older peptide GHRP-6 (swine ED50 of 2.3 nmol/kg versus 3.9 nmol/kg for GHRP-6) — yet it did not raise ACTH or cortisol above baseline even at doses more than 200-fold above its GH threshold [1]. That is the selectivity that gives this site its name: a strong signal with almost no off-target noise.
Want the mechanism in plain language first? Start with what does ipamorelin peptide do. Want the molecule itself? See what is ipamorelin peptide.
What the human data actually says
Human evidence is limited, and it is honest to say so. The cleanest human dataset is a pharmacokinetic study in eight healthy male volunteers per dose level: single intravenous infusions produced dose-proportional kinetics, a terminal half-life of roughly 2 hours, and a single GH pulse peaking about 40 minutes after dosing [2]. That tells you how the drug behaves in the body — fast in, fast out, one clean pulse.
What it doesn't tell you is whether ipamorelin treats anything. The only published Phase 2 trial put that to the test: 114 adults recovering from bowel surgery received ipamorelin intravenously, and the study missed its primary endpoint — median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo, a difference that was not statistically significant (p=0.15) [3]. No further clinical development followed. The honest read: the mechanism is real and elegant; the human outcome record is thin and, where tested, negative.
Signals from the animal record
The preclinical literature is where ipamorelin's profile is fleshed out. Subcutaneous ipamorelin dose-dependently increased the longitudinal bone-growth rate of adult rats — from 42 micrometers per day on vehicle up to 52 micrometers per day at the top dose — without measurably changing circulating IGF-1, suggesting part of the skeletal effect is driven locally by the GH pulse rather than by a sustained rise in IGF-1 [4]. (IGF-1, insulin-like growth factor 1, is the liver-made messenger that carries out many of growth hormone's downstream effects.)
The most recent in-vivo study, from 2024, found that ipamorelin blunted chemotherapy-driven weight loss in ferrets by about 24% during the delayed phase — a peripheral, body-composition effect — while having no anti-nausea action [5]. The throughline across three decades: a selective GH-pulse machine with real, reproducible effects on growth and body composition in animals, still awaiting a positive human outcome trial. The full breakdown lives in the Ipamorelin research digest.